ImmunityBio reported that its Phase 2 QUILT 3.078 study of the ANKTIVA® plus CAR‑NK combination in patients with recurrent or progressive glioblastoma achieved a median overall survival that has not yet been reached, with 19 of 23 enrolled patients alive as of January 22, 2026. Lymphopenia was reversed in the treated cohort, with absolute lymphocyte counts rising to ≥ 1.4 × 10³ /µL within one cycle and immune competence maintained throughout follow‑up.
The chemotherapy‑free regimen produced durable disease control, with 14 patients having evaluable data and a high proportion achieving complete responses—two near‑complete responses were observed in the pilot cohort and additional responses are expected as the study matures. The results validate the IL‑15 superagonist platform’s ability to synergize with off‑the‑shelf CAR‑NK cells, demonstrating a clinically meaningful benefit in a population that historically has a median overall survival of only six to nine months.
ImmunityBio’s commercial momentum for ANKTIVA is strong: preliminary Q4 2025 revenue reached $38.3 million, a 431% year‑over‑year increase, and full‑year 2025 revenue climbed to $113 million, up 700% YoY. The company’s cash position was $242.8 million as of December 31, 2025, providing a solid runway for continued clinical development and commercialization efforts.
Safety data from the combined QUILT 3.078 and single‑patient INDs showed a manageable profile, with three treatment‑related serious adverse events reported among 41 glioblastoma patients. No new safety signals emerged, and the safety profile aligns with expectations for the IL‑15 and CAR‑NK combination.
Strategically, the positive glioblastoma data expands ANKTIVA beyond its bladder‑cancer indication, reinforcing the company’s pipeline in non‑small‑cell lung cancer and other solid tumors. The results strengthen ImmunityBio’s competitive position, support a “strong buy” consensus among analysts, and underscore the platform’s versatility across tumor types.
Management highlighted the significance of the findings: CEO Richard Adcock said the data “demonstrate the power of our platform to restore immune competence and deliver durable responses without chemotherapy,” while founder Patrick Soon‑Shiong noted that the IL‑15 mechanism “plays an independent role across cancer types.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.